CN108653283A - Rapamycin and its derivative are preparing the purposes in treating bone loss disorders drug - Google Patents
Rapamycin and its derivative are preparing the purposes in treating bone loss disorders drug Download PDFInfo
- Publication number
- CN108653283A CN108653283A CN201810400174.5A CN201810400174A CN108653283A CN 108653283 A CN108653283 A CN 108653283A CN 201810400174 A CN201810400174 A CN 201810400174A CN 108653283 A CN108653283 A CN 108653283A
- Authority
- CN
- China
- Prior art keywords
- rapamycin
- purposes
- mouse
- ovx
- bone loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810400174.5A CN108653283A (en) | 2018-04-28 | 2018-04-28 | Rapamycin and its derivative are preparing the purposes in treating bone loss disorders drug |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810400174.5A CN108653283A (en) | 2018-04-28 | 2018-04-28 | Rapamycin and its derivative are preparing the purposes in treating bone loss disorders drug |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108653283A true CN108653283A (en) | 2018-10-16 |
Family
ID=63781391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810400174.5A Pending CN108653283A (en) | 2018-04-28 | 2018-04-28 | Rapamycin and its derivative are preparing the purposes in treating bone loss disorders drug |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108653283A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110151747A (en) * | 2019-03-29 | 2019-08-23 | 徐又佳 | Purposes of the Ferrostatin-1 in treatment bone loss disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1820011A (en) * | 2003-07-08 | 2006-08-16 | 诺瓦提斯公司 | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
-
2018
- 2018-04-28 CN CN201810400174.5A patent/CN108653283A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1820011A (en) * | 2003-07-08 | 2006-08-16 | 诺瓦提斯公司 | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
Non-Patent Citations (8)
Title |
---|
MENG QI ET AL: "Autophagy Maintains the Function of Bone Marrow Mesenchymal Stem Cells to Prevent Estrogen Deficiency-Induced Osteoporosis", 《THERANOSTICS》 * |
SILVIA COLUCCI ET AL: "The Immunophilin FKBP12 Inhibits Hepcidin Expression by Binding the BMP Type I Receptor ALK2 in Hepatocytes", 《BLOOD》 * |
刘禄林等: "铁过载对去势大鼠骨代谢的影响", 《中华骨质疏松和骨矿盐疾病杂志》 * |
戚朦: "自噬在***缺乏骨质疏松小鼠骨髓间充质干细胞分化平衡中的作用研", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
李光飞等: "铁蓄积与绝经后骨质疏松症关系的研究进展", 《中华骨科杂志》 * |
沈光思: "铁调素对骨代谢影响的实验研究", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
谭清梅等: "雷帕霉素延缓老年小鼠脊柱退变的实验研究", 《中国骨质疏松杂志》 * |
赵国阳: "铁过载对骨代谢的影响及其相关机制的研究", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110151747A (en) * | 2019-03-29 | 2019-08-23 | 徐又佳 | Purposes of the Ferrostatin-1 in treatment bone loss disorders |
CN110151747B (en) * | 2019-03-29 | 2021-05-11 | 徐又佳 | Application of Ferrostatin-1 in treating osteoporosis diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220265682A1 (en) | Drug composition containing abiraterone acetate, and preparation method therefor and application thereof | |
AU2020203867A1 (en) | Cenicriviroc for the treatment of fibrosis | |
AU2016323468A1 (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
CN110536702A (en) | Use the method for HSP90 inhibitor for treating cancer | |
RU2649129C2 (en) | USE OF RECOMBINANT GANODERMA LUCIDUM IMMUNOMODULATORY PROTEIN (rLZ-8) IN PREPARATION OF MEDICINE FOR TREATING MELANOMA | |
CA2664935A1 (en) | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c | |
CN109922803A (en) | The purposes of 2 inhibitor of lysyloxidase sample | |
CN111265527B (en) | Application of naphthoquine and pharmaceutically acceptable salt thereof in preparation of anti-coronavirus medicines | |
US20230226140A1 (en) | Ang (1-7) derviative oligopeptides for the treatment of pain | |
KR20210053948A (en) | PDE9 inhibitors for treatment of sickle cell disease | |
CN108367001A (en) | Treat hepatitis delta viral infection | |
KR20120008069A (en) | Antitumor combination including cabazitaxel and capecitabine | |
CN108653283A (en) | Rapamycin and its derivative are preparing the purposes in treating bone loss disorders drug | |
JP2008514721A (en) | Method of treatment | |
KR20200128510A (en) | How to treat lymphoid malignancies | |
JP2017536403A (en) | Treatment of hepatitis delta virus infection | |
WO2021053651A1 (en) | Extract of cocculus hirsutus for treatment of covid-19 | |
CN110151747A (en) | Purposes of the Ferrostatin-1 in treatment bone loss disorders | |
CN109260214A (en) | Application of the paeoniflorin compound in preparation treatment medication for treating pyemia | |
EP3782620B1 (en) | Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia | |
US20070161704A1 (en) | Pharmaceutical composition useful for treating chronic myeloid leukemia | |
US8206760B2 (en) | Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient | |
JPH01149730A (en) | Retrovirus proliferation inhibitor | |
CN112773802B (en) | Use of compound for preventing or treating graft-versus-host disease | |
CA2262765A1 (en) | Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Aifei Inventor after: Wang Xiao Inventor after: Li Guangfei Inventor after: Chen Bin Inventor after: Yang Fan Inventor after: Xu Youjia Inventor after: Yi Nan Inventor before: Wu Jiadong Inventor before: Wang Aifei Inventor before: Wang Xiao Inventor before: Li Guangfei Inventor before: Chen Bin Inventor before: Yang Fan Inventor before: Xu Youjia Inventor before: Yi Nan |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181016 |